Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: A randomized, dose-ranging, double-blind, phase 2 study

Genovefa A. Papanicolaou, Fernanda P. Silveira, Amelia A. Langston, Marcus R. Pereira, Robin K. Avery, Marc Uknis, Anna Wijatyk, Jingyang Wu, Michael Boeckh, Francisco M. Marty, Stephen Villano

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Fingerprint

Dive into the research topics of 'Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: A randomized, dose-ranging, double-blind, phase 2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences